Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis

Journal of Clinical Pathology

Volumn 64, Issue 4, 2011, Pages 354-357

  Jabbar, Suhair ^a   Drury, John ^a   Fordham, John N ^a   Datta, Harish K ^b   Francis, Roger M ^c   Tuck, Stephen P ^a  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; BIOCHEMICAL MARKER; ESTRADIOL; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; SEX HORMONE;

ADULT; AGE; ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; ESTRADIOL BLOOD LEVEL; FEMALE; FEMUR NECK; HUMAN; IMMOBILIZATION; LIFESTYLE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; SEX RATIO; VITAMIN BLOOD LEVEL; WEIGHT REDUCTION;

ABSORPTIOMETRY, PHOTON; AGED; ANTHROPOMETRY; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; RANK LIGAND;

EID: 79953103736     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.086595     Document Type: Article

References (25)

1. Anon. Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-50.
2. van Staa TP, Dennison EM, Leufkens HG, et al. Epidemiology of fractures in England and Wales. Bone 2001;29:517-22. (Pubitemid 33124293)
3. Jackson RD, Donepudi S, Mysiw WJ. Epidemiology of fracture risk in the Women's Health Initiative. Curr Osteoporos Rep 2008;6:155-61.
4. Donaldson LJ, Reckless IP, Scholes S, et al. The epidemiology of fractures in England. J Epidemiol Community Health 2008;62:174-80. (Pubitemid 351196859)
5. Russell RG. Pathogenesis of Osteoporosis. In: Hochberg MC, Silman AJ, Smolen SJ, et al, eds. Rheumatology. 3rd edn. New York: Mosby, 2003:2075-147.
6. Cooper C, Westlake S, Harvey N. Review: developmental origins of osteoporotic fracture. Osteoporosis Int 2006;17:337-47.
7. Ng MY, Sham PC, Paterson AD, et al. Effect of environmental factors and gender on the heritability of bone mineral density and bone size. Ann Hum Genet 2006;70:428-38. (Pubitemid 43797352)
8. Jakob F, Seefried L, Ebert R. Pathophysiology of bone metabolism. Internist (Berl) 2008;49:1159-60.
9. Datta HK, Ng WF, Walker JA, et al. Cell biology of bone. J Clin Pathol 2008;61:577-87.
10. Nakamura M, Nakamichi Y, Nakamura H, et al. Osteoclastogenesis and bone resorption. Nippon Rinsho 2009;67:889-96.
11. Gallagher JC. Advances in bone biology and new treatments for bone loss. Maturitas 2008;60:65-9.
12. Leibbrandt A, Penninger JM. RANK (L) as a key target for controlling bone loss. Adv Exp Med Biol 2009;647:130-45.
13. Morabito N, Gaudio A, Lasco A, et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 2004;19:727-7.
14. Mezquita RP, de la Hquera M, Garcia DF, et al. The contribution of plasma osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporosis Int 2005;16:1368-74. (Pubitemid 41532089)
15. Abdallah BM, Stilgren LS, Nissen N, et al. Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. Calcified Tissue Int 2005;76:90-7. (Pubitemid 40684955)
16. Ulivieri FM, Piodi LP, Marchelli D, et al. Osteoprotegerin: a valid new marker of bone turnover in post-menopausal osteoporosis? J Orthop Traumatol 2005;6:88-90.
17. Stern A, Laughlin GA, Bergstrom J, et al. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor B legend with bone mineral density in older adults: the Rancho Bernardo Study. Eur J Endocrinol 2007;156:555-62. (Pubitemid 46796522)
18. Chiba Y, Onouchi T, Ikeda T, et al. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women. Gerontology 2009;55:275-80.
19. Nabipour I, Larijani B, Vahdat K, et al. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory. Menopause 2009;16:950-5.
20. Liu JM, Zhao HY, Ning G, et al. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in chinese women aged 20-75. Calcif Tissue Int 2005;76:1-6. (Pubitemid 40228467)
21. Jabber S, Drury J, Fordham J, et al. Plasma vitamin D and cytokines in periodontol disease and postmenopausal osteoporosis. J Periodontal Res 2011;46:97-104.
22. O'Neill TW, Copper C, Cannata JR. Reproducibility of a questionnaire on risk factors for osteoporosis in a multicentre prevalence survey: the European Vertebral Osteoporosis Study. Int J Epidemiol 1994;23:359-65.
23. Szulc P, Hofabuer LC, Heufelder AE, et al. Osteoprotegerin plasma levels in men: correlation with age, estrogen and testosterone status. J Clin Endocrinol Metab 2001;86:31625.
24. Browner WS, Lui L, Cummings SR. Associations of plasma osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631-7. (Pubitemid 32207471)
25. Indridason O, Franzson L, Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporosis Int 2005;16:417-23. (Pubitemid 40487400)